KV Pharmaceutical To Decide Whether To Retain Generics Business After Settling Manufacturing Cover-up Charges With DoJ
KV Pharmaceutical is ceasing the operations of its generics subsidiary, Ethex Corp., in the wake of a plea agreement with the Department of Justice and it is uncertain what will become of the business
You may also be interested in...
KV clears major hurdle as court okays its chapter 11 reorganization plan, which provides for payment of $23.4 million owed under 2010 Department of Justice settlement and $231.4 million for senior notes; firm’s future remains tied to Makena.
Although pharmaceutical company settlements in the millions of dollars now seem customary, a guilty plea to seven felonies could signal aggressive government pursuit of manufacturing and data integrity concerns.
During a hearing in the company’s lawsuit against FDA, a federal judge repeatedly questions her authority to require the agency take enforcement action against compounding pharmacies; KV filed for bankruptcy protection three days earlier, citing its inability to realize full value of the pre-term birth drug due to competition from cheaper compounded versions of 17-P.